Ratings Mersana Therapeutics, Inc.

Equities

MRSN

US59045L1061

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-26 pm EDT			5-day change	1st Jan Change
2.94 ^USD	+3.16%		-9.54%	+26.72%

Mar. 20	North American Morning Briefing : Markets on Hold -2-	DJ
Mar. 19	JPMorgan Upgrades Mersana Therapeutics to Neutral From Underweight, Price Target is $5	MT

Summary

Overall, the company has poor fundamentals for a medium to long-term investment strategy.

Strengths

Growth remains a strong point in this company. In their sales forecast, analysts sound optimistic with regard to sales prospects.
For the last twelve months, analysts have been gradually revising upwards their EPS forecast for the upcoming fiscal year.
Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
The average price target of analysts who are interested in the stock has been strongly revised upwards over the last four months.
Analyst opinion has improved significantly over the past four months.

Weaknesses

According to Standard & Poor's' forecast, revenue growth prospects are expected to be very low for the next fiscal years.
The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
Low profitability weakens the company.
One of the major weak points of the company is its financial situation.
Based on current prices, the company has particularly high valuation levels.
For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
Over the past twelve months, analysts' consensus has been significantly revised downwards.
Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.

Ratings chart - Surperformance

Chart ESG Refinitiv

Sector: Biotechnology & Medical Research

	1st Jan change	Capi.	ESG Refinitiv
MERSANA THERAPEUTICS, INC.	+26.72%	346M	B-
VERTEX PHARMACEUTICALS INCORPORATED	-2.31%	103B	B+
REGENERON PHARMACEUTICALS, INC.	+0.56%	95.71B	B+
ARGENX SE	+1.69%	22.02B	B
BIONTECH SE	-17.37%	20.9B	B+
GENMAB A/S	-9.30%	17.85B	A-
WUXI APPTEC CO., LTD.	-41.01%	16.21B	A-
BEIGENE, LTD.	-14.85%	15.52B	B
NEUROCRINE BIOSCIENCES, INC.	+3.21%	13.86B	C+
SAREPTA THERAPEUTICS, INC.	+33.54%	12.04B	C+

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Environment

Emissions

Innovation

Use of resources

Governance

CSR Strategy

Management

Shareholders

Controversy

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes